133 related articles for article (PubMed ID: 33608055)
21. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
[TBL] [Abstract][Full Text] [Related]
22. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment.
Makis AC; Hatzimichael EC; Kolios G; Bourantas KL
Haematologica; 2004 Mar; 89(3):360-1. PubMed ID: 15020278
[TBL] [Abstract][Full Text] [Related]
23. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y; Miller ST; Kanter J; Lanzkron S; Smith WR; Hsu LL; Gordeuk VR; Viswanathan K; Sarnaik S; Osunkwo I; Guillaume E; Sadanandan S; Sieger L; Lasky JL; Panosyan EH; Blake OA; New TN; Bellevue R; Tran LT; Razon RL; Stark CW; Neumayr LD; Vichinsky EP;
N Engl J Med; 2018 Jul; 379(3):226-235. PubMed ID: 30021096
[TBL] [Abstract][Full Text] [Related]
24. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Okam MM; Ebert BL
Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
[TBL] [Abstract][Full Text] [Related]
25. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
26. Severity of Brazilian sickle cell disease patients: severity scores and feasibility of the Bayesian network model use.
Belini Junior E; Silva DG; Torres Lde S; Okumura JV; Lobo CL; Bonini-Domingos CR
Blood Cells Mol Dis; 2015 Apr; 54(4):321-7. PubMed ID: 25842370
[TBL] [Abstract][Full Text] [Related]
27. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
28. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
Rodgers GP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
[TBL] [Abstract][Full Text] [Related]
29. Five years of experience with hydroxyurea in children and young adults with sickle cell disease.
Ferster A; Tahriri P; Vermylen C; Sturbois G; Corazza F; Fondu P; Devalck C; Dresse MF; Feremans W; Hunninck K; Toppet M; Philippet P; Van Geet C; Sariban E
Blood; 2001 Jun; 97(11):3628-32. PubMed ID: 11369660
[TBL] [Abstract][Full Text] [Related]
30. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.
Jayabose S; Tugal O; Sandoval C; Patel P; Puder D; Lin T; Visintainer P
J Pediatr; 1996 Oct; 129(4):559-65. PubMed ID: 8859263
[TBL] [Abstract][Full Text] [Related]
31. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
[TBL] [Abstract][Full Text] [Related]
32. Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
Wood KC; Granger DN
Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):926-32. PubMed ID: 17645642
[TBL] [Abstract][Full Text] [Related]
33. Hydroxyurea, sickle cell disease and renal transplantation.
Allen A; Scoble J; Snowden S; Hambley H; Bellingham A
Nephron; 1997; 75(1):106-7. PubMed ID: 9031282
[No Abstract] [Full Text] [Related]
34. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
[TBL] [Abstract][Full Text] [Related]
35. Does increased red blood cell deformability raise the risk for osteonecrosis in sickle cell anemia?
Lemonne N; Lamarre Y; Romana M; Mukisi-Mukaza M; Hardy-Dessources MD; Tarer V; Mougenel D; Waltz X; Tressières B; Lalanne-Mistrih ML; Etienne-Julan M; Connes P
Blood; 2013 Apr; 121(15):3054-6. PubMed ID: 23580637
[No Abstract] [Full Text] [Related]
36. Study of Seminal Fluid Parameters and Fertility of Male Sickle Cell Disease Patients and Potential Impact of Hydroxyurea Treatment.
Sahoo LK; Kullu BK; Patel S; Patel NK; Rout P; Purohit P; Meher S
J Assoc Physicians India; 2017 Jun; 65(6):22-25. PubMed ID: 28782309
[TBL] [Abstract][Full Text] [Related]
37. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
[TBL] [Abstract][Full Text] [Related]
38. Hydroxyurea in the treatment of sickle-cell anemia.
Howard LW; Kennedy LD
Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
[TBL] [Abstract][Full Text] [Related]
39. Ten-year review of hospital admissions among children with sickle cell disease in Kuwait.
Akar NA; Adekile A
Med Princ Pract; 2008; 17(5):404-8. PubMed ID: 18685282
[TBL] [Abstract][Full Text] [Related]
40. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.
Styles LA; Lubin B; Vichinsky E; Lawrence S; Hua M; Test S; Kuypers F
Blood; 1997 Apr; 89(7):2554-9. PubMed ID: 9116302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]